Sulfonamide compounds

Details Sulfonamide compounds Sulfonamide compounds

2007-11-20

2007-11-20

Richter, Johann (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C558S410000

Reexamination Certificate

active

11230249

ABSTRACT:
Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

REFERENCES:
patent: 4507315 (1985-03-01), Ashton et al.
patent: 6239131 (2001-05-01), Shinozaki et al.
patent: 2002/0193422 (2002-12-01), Brendel et al.
patent: 2004/0224983 (2004-11-01), Allison et al.
patent: 2005/0038032 (2005-02-01), Allison et al.
patent: 2005/0042283 (2005-02-01), Want et al.
patent: 2006/0069286 (2006-03-01), Allison et al.
patent: 3330403 (1984-03-01), None
patent: 0508796 (1992-10-01), None
patent: WO 02087568 (2002-11-01), None
patent: WO 02088073 (2002-11-01), None
patent: WO 02100825 (2002-12-01), None
patent: WO 2004/106306 (2004-12-01), None
patent: WO 2004/106310 (2004-12-01), None
patent: WO 2004/106315 (2004-12-01), None
patent: WO 2004/106315 (2004-12-01), None
International Search Report re: PCT/US2005/033692 dated Feb. 28, 2006.
Black, J.W. and S.B. Kalindjian. Gastrin Agonists and Antagonists.Pharmacol. Toxicol. 2002, 91, 275-281.
Boeckxstaens, G. E. et al. Involvement of Cholecystokinin A Receptors in Transient Lower Esophageal Sphincter Relaxations Triggered by Gastric Distension.Am. J. Gastroenterol. 1998, 93(10), 1823-1828.
Boulant, J. et al. Cholecystokinin and Nitric Oxide in Transient Lower Esophageal Sphincter Relaxation to Gastric Distention in Dogs.Gastroenterology1994, 107(4), 1059-1066.
Boulant, J. et al. Cholecystokinin in Transient Lower Oesophageal Sphincter Relaxation Due to Gastric Distension in Humans.Gut1997, 40(5), 575-581.
de Tullio, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands. Exp. Opin. Invest. Drugs 2000, 9(1), 129-146.
Harper, E.A. et al. Analysis of Variation in L-365,260 Competition Curves in Radioligand Binding Assays.Br. J. Pharmacol. 1996, 118, 1717-1726.
Herranz, R. Cholecystokinin Antagonists: Pharmacological and Therapeutic Potential.Med. Res. Rev. 2003, 23(5), 559-605.
Hirsch, D. P. et al. Role of CCKAReceptors in Postprandial Lower Esophageal Sphincter Function in Morbidly Obese Subjects.Dig. Dis. Sci. 2002, 47(11), 2531-2537.
Holloway, R. H. Systemic Pharmacomodulation of Transient Lower Esophageal Sphincter Relaxations.Am. J. Med. 2001, 111(8A), 178S-185S.
Hull, R.A.D. et al. 2-Naphthalenesulphonyl L-Aspartyl-(2-phenethyl)amide (2-NAP)—A Selective Cholecystekinin CCKA-Receptor Antagonist. Br. J. Pharmacol. 1993, 108:734-740.
Parson, M. E. and D.J. Keeling. Novel Approaches to the Pharmacological Blockade of Gastric Acid Secretion.Exp. Opin. Invest. Drugs2005, 14(4), 411-421.
Roberts, S.P. et al. Analysis of the Variation in the Action of L-365,260 at CCK8/Gastrin Receptors in Rat, Guinea-pig and Mouse Isolated Gastric Tissue Assays. Br. J. Pharmacol., 1996, 118(7), 1779-1789.
Stark, H. et al. Neue Wirkstoffe zur GERD-Behandlung.Pharm. Unserer Zeit2005, 34(3), 224-227. (English language abstract attached).
Tabuchi, S. et al. Dual CCK-A and CCK-B Receptor Antagonists (II). Preparation and Structure Activity Relationships of 5-Alkyl-9-methyl-1,4-benzodiazepines and Discovery of FR208419.Chem. Pharm. Bull. 2000, 48(1), 1-15.
Tracy, H.J. and R.A. Gregory. Physicological Properties of a Series of Synthetic Peptides Structurally Related to Gastrin I.Nature(London) 1964, 204, 935-938.
Tonini, M. et al. Progress with Novel Pharmaceutical Strategies for Gastro-oesophageal Reflux Disease.Drugs2004, 64(4), 347-361.
Trudgill, N. J. et al. The Effect of Cholecystokinin Antagonism on Postprandial Lower Esophageal Sphincter Function in Asymptomatic Volunteers and Patients with Reflux Disease.Aliment. Pharmacol. Ther. 2001, 15(9), 1357-1364.
Varnavas, A. et al. Anthranilic Acid Based CCK1 Antagonists: The 2-Indole Moiety May Represent a “Needle” According to the Recent Homonymous Concept.Eur. J. Med. Chem. 2004, 39, 85-97.
Varnavas, A. et al. Anthranilic Acid Derivatives: A New Class of Non-Peptide CCK1Receptor Antagonists.Bioorg. Med. Chem. 2003, 11, 741-751.
Varnavas, A. et al. Synthesis of N-Terminal Substituted Anthranilic Acid Dimer Derivatives for Evaluation on CCK Receptors.II Farmaco2001, 56, 555-564.
Gavezzotti, “Are Crystal Structures Predictable?”, Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Lewis, Sr., Richard J., Hawley's Condensed Chemical Dictionary, 13thed., 1997 by Van Nostrand Reinhold, p. 587.
Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).

Affiliated with

Also associated with

Rating

Sulfonamide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonamide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3830064